MedPath

MANTA Registry for Vascular Large-bore Closure

Completed
Conditions
Femoral Arteriotomy Closure
Registration Number
NCT03330002
Lead Sponsor
Essential Medical, Inc.
Brief Summary

The aim of this observational post market study is to compile real world outcome data on the use of the Conformité Européenne (CE) marked MANTA Vascular Closure Device following percutaneous cardiac or peripheral procedures for large bore (10-18F ID) interventional devices.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants With One or More Major Access Site Related Complicationswithin 30 days of procedure

Major access site related complications adapted from the VARC-2 definitions

Time to HemostasisImmediately after deployment of MANTA VCD

The elapsed time between MANTA deployment (withdrawal of sheath from artery) and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).

Secondary Outcome Measures
NameTimeMethod
Number of Participants With One or More Minor Access Site Related Complicationswithin 30 days of procedure

Minor access site related complications adapted from the VARC-2 definitions

Trial Locations

Locations (9)

St Paul's Hospital

🇨🇦

Vancouver, Canada

Vancouver General Health

🇨🇦

Vancouver, Canada

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

Helsinki University Hospital

🇫🇮

Helsinki, Finland

University of Turku

🇫🇮

Turku, Finland

OLVG

🇳🇱

Amsterdam, Netherlands

Catharina Ziekenhuis

🇳🇱

Eindhoven, Netherlands

Erasmus Medical Center

🇳🇱

Rotterdam, Netherlands

Luzerner Kantonsspital

🇨🇭

Luzern, Switzerland

St Paul's Hospital
🇨🇦Vancouver, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.